174,866 Shares in CVS Health Corporation $CVS Acquired by CIBC Bancorp USA Inc.

CIBC Bancorp USA Inc. acquired a new stake in CVS Health Corporation (NYSE:CVS) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 174,866 shares of the pharmacy operator’s stock, valued at approximately $13,183,000.

A number of other large investors have also modified their holdings of the business. Harbor Capital Advisors Inc. grew its stake in CVS Health by 72.1% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 339 shares of the pharmacy operator’s stock valued at $26,000 after acquiring an additional 142 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in CVS Health by 407.2% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after purchasing an additional 281 shares in the last quarter. Corundum Trust Company INC purchased a new position in CVS Health in the 3rd quarter worth approximately $29,000. Front Row Advisors LLC boosted its holdings in shares of CVS Health by 436.5% during the 2nd quarter. Front Row Advisors LLC now owns 456 shares of the pharmacy operator’s stock worth $31,000 after purchasing an additional 371 shares during the last quarter. Finally, Twin Peaks Wealth Advisors LLC purchased a new stake in shares of CVS Health in the second quarter valued at approximately $36,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Performance

Shares of CVS Health stock opened at $71.86 on Friday. The firm has a market cap of $91.41 billion, a PE ratio of 52.07, a price-to-earnings-growth ratio of 0.76 and a beta of 0.49. The company has a quick ratio of 0.63, a current ratio of 0.84 and a debt-to-equity ratio of 0.80. CVS Health Corporation has a 52 week low of $58.35 and a 52 week high of $85.15. The business’s fifty day simple moving average is $77.66 and its 200-day simple moving average is $77.79.

CVS Health (NYSE:CVS) last issued its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.00 by $0.09. The firm had revenue of $105.69 billion for the quarter, compared to analyst estimates of $103.67 billion. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. CVS Health’s revenue was up 8.2% on a year-over-year basis. During the same period in the previous year, the firm earned $1.19 EPS. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 4th. Stockholders of record on Thursday, April 23rd will be issued a $0.665 dividend. This represents a $2.66 annualized dividend and a dividend yield of 3.7%. The ex-dividend date is Thursday, April 23rd. CVS Health’s dividend payout ratio is currently 192.75%.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Board-approved quarterly dividend of $0.665/share (payable May 4, 2026), supporting income investors and signaling confidence in cash flow. CVS Health declares quarterly dividend
• Positive Sentiment: CVS Health Foundation commits $2.24M to a Health Zone in Charlotte’s Historic West End — positive for brand, community relations and ESG positioning. CVS Health Foundation Invests $2.24 Million
• Neutral Sentiment: Company executive discussed CVS/Aetna AI policy and quality trade-offs — indicates management focus on AI governance but no immediate financial impact disclosed. CVS Health/Aetna executive discusses company AI policy
• Neutral Sentiment: CVS is getting increased retail investor attention; Zacks/Yahoo pieces note the stock is trending and review fundamentals — may boost trading volume but not a directional fundamental driver. CVS trending stock: Zacks
• Neutral Sentiment: CVS executive Dana Prommel Strauss joins Bioliberty board — adds industry expertise and partnership potential, limited short-term stock impact. Bioliberty Raises $10.2 million
• Neutral Sentiment: Company confirms it will remain at the Somerset distribution site despite a potential sale — operational stability for the supply chain. CVS to remain at Somerset distribution
• Negative Sentiment: New Tennessee legislation targeting PBMs (the “Fair Rx” proposals) could force changes to PBM practices and, per reports, threaten closure of 100+ CVS stores in the state — raises regulatory and revenue risk in a meaningful local market. TN bill could threaten closure of 100+ CVS stores
• Negative Sentiment: Tennessee House finance committee has moved the Fair Rx Act forward amid public dispute with CVS — legislative momentum increases near-term political/regulatory risk for the PBM model. TN House finance committee moves Fair Rx Act
• Negative Sentiment: Class-action racketeering lawsuit filed by Bernstein Litowitz against CaremarkPCS and CVS alleges PBM fraud—adds legal exposure and potential reputational/financial risk. BLB&G files racketeering class action

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of CVS Health in a report on Monday, December 29th. Leerink Partners restated an “outperform” rating and issued a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. Barclays lifted their price target on CVS Health from $87.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. Morgan Stanley boosted their price target on shares of CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, December 10th. Finally, Bank of America cut their price objective on shares of CVS Health from $100.00 to $95.00 and set a “buy” rating for the company in a research report on Tuesday, January 27th. Twenty equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $95.05.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.